Characteristics and survival of patients with acute leukemia (n = 61)
| Disease risk and remission status . | n . | Alive in remission . | Relapsed and alive . | Relapse-related mortality . | TRM . |
|---|---|---|---|---|---|
| AML in complete remission (n = 40) | |||||
| ELN favorable* | 6 | 6 | |||
| CR1 MRD− | 5 | 5 | |||
| CR2 MRD− | 1 | 1 | |||
| ELN intermediate 1/2† | 25 | 20 | 1 | — | 4 |
| CR1 MRD− | 14 | 12 | 1 (NPM1+ and FLT3-ITD) | 1 | |
| CR1 MRD+ | 7 | 6 | 1 | ||
| CR1 MRD unknown | 2 | 1 | 2 | ||
| CR2 MRD+ | 1 | 1 | |||
| CR2 MRD unknown | 1 | ||||
| ELN adverse‡ | 9 | 6 | 1 | 1 | 1 |
| CR1 MRD− | 3 | 3 | |||
| CR1 MRD+ | 3 | 2 | 1 | ||
| CR1 MRD unknown | 2 | 1 | 1 [del(5q)] | 1 (MLL rearrangement) | |
| CR2 MRD− | 1 | ||||
| AML, relapsed/refractory (n = 4) | |||||
| ELN intermediate 1/2§ | 2 | 2 | |||
| ELN adverse|| | 2 | 1 | 1 | ||
| ALL in complete remission (n = 13)¶ | |||||
| CR1 MRD− | 3 | 2 | 1 | ||
| CR1 MRD+ | 3 | 2 | 1 | ||
| CR2 MRD+ | 2 | 2 | |||
| CR2 MRD− | 5 | 4 | 1 | ||
| MPAL in complete remission (n = 4)# | |||||
| CR1 MRD− | 2 | 2 | |||
| CR1 MRD+ | 2 | 1 | 1 | ||
| Disease risk and remission status . | n . | Alive in remission . | Relapsed and alive . | Relapse-related mortality . | TRM . |
|---|---|---|---|---|---|
| AML in complete remission (n = 40) | |||||
| ELN favorable* | 6 | 6 | |||
| CR1 MRD− | 5 | 5 | |||
| CR2 MRD− | 1 | 1 | |||
| ELN intermediate 1/2† | 25 | 20 | 1 | — | 4 |
| CR1 MRD− | 14 | 12 | 1 (NPM1+ and FLT3-ITD) | 1 | |
| CR1 MRD+ | 7 | 6 | 1 | ||
| CR1 MRD unknown | 2 | 1 | 2 | ||
| CR2 MRD+ | 1 | 1 | |||
| CR2 MRD unknown | 1 | ||||
| ELN adverse‡ | 9 | 6 | 1 | 1 | 1 |
| CR1 MRD− | 3 | 3 | |||
| CR1 MRD+ | 3 | 2 | 1 | ||
| CR1 MRD unknown | 2 | 1 | 1 [del(5q)] | 1 (MLL rearrangement) | |
| CR2 MRD− | 1 | ||||
| AML, relapsed/refractory (n = 4) | |||||
| ELN intermediate 1/2§ | 2 | 2 | |||
| ELN adverse|| | 2 | 1 | 1 | ||
| ALL in complete remission (n = 13)¶ | |||||
| CR1 MRD− | 3 | 2 | 1 | ||
| CR1 MRD+ | 3 | 2 | 1 | ||
| CR2 MRD+ | 2 | 2 | |||
| CR2 MRD− | 5 | 4 | 1 | ||
| MPAL in complete remission (n = 4)# | |||||
| CR1 MRD− | 2 | 2 | |||
| CR1 MRD+ | 2 | 1 | 1 | ||
AML favorable: inv(16) (n = 2); t(8;21) (n = 1); normal karyotype and NPM1+, FLT3 WT (n = 3).
AML intermediate 1 (normal karyotype) (n = 14): NPM1+ and FLT3-ITD (n = 7), WT NPM1 and FLT3-ITD (n = 2), and WT NPM1 without FTL3-ITD (n = 5). AML intermediate 2 (n = 11): t(9;11) (n = 1), cytogenetic abnormalities not defined as favorable or adverse (n = 10). Three intermediate 2 risk patients were FLT3-ITD–positive.
AML adverse: complex karyotype (n = 5), −7 (n = 1), del(5q) (n = 1), MLL rearranged (n = 2). Three adverse risk patients were FLT3-ITD–positive.
AML relapsed/ refractory: intermediate 1, WT NPM1 without FTL3-ITD (n = 1); intermediate 2, cytogenetic abnormalities not defined as favorable or adverse and FLT3-ITD (n = 1).
AML relapsed/refractory: complex karyotype (n = 1), −7 (n = 1).
ALL: Ph+ (n = 2) and Ph− (n = 11).
MPAL: Ph+ (n = 1); other (n = 3).